Eledon PharmaceuticalsELDN
13F holders, Q3 2024 (September 30)33holders +1
2new positions
1sold out
1famous investor
$2.49avg. 13F price*
At the end of Q3 2024, 33 institutions reported holding Eledon Pharmaceuticals Inc. (ELDN) in their 13F filings, up 1 from Q2 2024. 2 opened new positions and 1 sold out. The largest holders were BVF Inc. ($15.7M), Armistice Capital, LLC ($5.9M) and Vanguard Group Inc. ($3.9M). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Eledon Pharmaceuticals Inc.
- CUSIP
- 28617K101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $56K |
| Exits | 1 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 913,449 shares bought and 748,260 shares sold, net +165,189 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 33 holders
| BVF Inc. | 0.46% | No change | 6,293,282 | $15.7M |
| Armistice Capital, LLC | 0.15% | Add +1.2% | 2,364,000 | $5.9M |
| Vanguard Group Inc. | 0.00% | Add +41.8% | 1,565,487 | $3.9M |
| Schonfeld Strategic Advisors LLC | 0.03% | No change | 1,500,000 | $3.7M |
| Zimmer Partners, LP | 0.07% | Reduce -32.0% | 1,434,727 | $3.6M |
| Sphera Funds Management LTD. | 0.53% | Add +0.0% | 1,297,321 | $3.2M |
| Woodline Partners LP | 0.02% | Add +24.8% | 842,892 | $2.1M |
| Nantahala Capital Management, LLC | 0.13% | No change | 600,000 | $1.5M |
| Alyeska Investment Group, L.P. | 0.01% | No change | 500,000 | $1.2M |
| Ensign Peak Advisors, Inc | 0.00% | No change | 443,001 | $1.1M |
| Geode Capital Management, LLC | 0.00% | Add +9.7% | 378,058 | $942K |
| CM Management, LLC | 0.55% | Add +71.9% | 275,000 | $685K |
| BlackRock, Inc. | 0.00% | — | 215,868 | $538K |
| State Street Corp. | 0.00% | No change | 161,492 | $402K |
| Renaissance Technologies | 0.00% | Reduce -0.7% | 135,873 | $338K |
| Northern Trust Corp. | 0.00% | No change | 91,893 | $229K |
| Morgan Stanley | 0.00% | Add +3773.4% | 83,471 | $208K |
| Jmac Enterprises LLC | 0.02% | No change | 58,041 | $145K |
| Ingalls & Snyder LLC | 0.01% | No change | 51,849 | $129K |
| Dimensional Fund Advisors LP | 0.00% | Add +13.2% | 34,223 | $85K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 33,400 | $83K |
| Marco Investment Management LLC | 0.01% | No change | 30,344 | $76K |
| Susquehanna International Group, LLP | 0.00% | Reduce -8.8% | 19,870 | $49K |
| Mercer Global Advisors Inc. | 0.00% | No change | 16,726 | $41K |
| Charles Schwab Investment Management Inc. | 0.00% | No change | 14,987 | $37K |
| Pathstone Holdings, LLC | 0.00% | No change | 13,029 | $32K |
| Clarity Capital Partners LLC | 0.02% | New | 11,500 | $29K |
| Two Sigma Securities, LLC | 0.00% | New | 11,027 | $27K |
| Bank of America Corp. | 0.00% | Reduce -0.0% | 6,816 | $17K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -91.0% | 1,532 | $4K |
| JPMorgan Chase & Co. | 0.00% | Add +6.6% | 97 | $242 |
| FMR LLC | 0.00% | No change | 17 | $42 |
| UBS Group AG | 0.00% | Reduce -100.0% | 4 | $10 |
"% of holder's portfolio" is ELDN's weight in each manager's 13F, not the share of Eledon Pharmaceuticals Inc. the manager owns.